These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 20073128

  • 1. IgG2m4, an engineered antibody isotype with reduced Fc function.
    An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, Harvey BR, Montgomery D, Zaller D, Wang F, Strohl W.
    MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
    [Abstract] [Full Text] [Related]

  • 2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.
    Methods; 2014 Jan 01; 65(1):114-26. PubMed ID: 23872058
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
    Moore GL, Chen H, Karki S, Lazar GA.
    MAbs; 2010 Jan 01; 2(2):181-9. PubMed ID: 20150767
    [Abstract] [Full Text] [Related]

  • 5. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
    Kellner C, Derer S, Klausz K, Rosskopf S, Wirt T, Rösner T, Otte A, Cappuzzello E, Peipp M.
    Methods Mol Biol; 2018 Jan 01; 1827():381-397. PubMed ID: 30196508
    [Abstract] [Full Text] [Related]

  • 6. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, Behrens CK, Mondon P, Fontayne A.
    MAbs; 2014 Jan 01; 6(2):422-36. PubMed ID: 24492301
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D, Goldberg MV, Chiu ML.
    J Biol Chem; 2016 Dec 30; 291(53):27134-27146. PubMed ID: 27856634
    [Abstract] [Full Text] [Related]

  • 11. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    Burvenich IJG, Farrugia W, Liu Z, Makris D, King D, Gloria B, Perani A, Allan LC, Scott AM, Ramsland PA.
    Biochem J; 2018 Jul 05; 475(13):2179-2190. PubMed ID: 29794155
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
    Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG.
    J Immunol; 2000 Apr 15; 164(8):4178-84. PubMed ID: 10754313
    [Abstract] [Full Text] [Related]

  • 15. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
    Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJ, Watts RJ, Couch JA, Meng YG, Atwal JK, Brezski RJ, Spiess C, Ernst JA.
    J Biol Chem; 2017 Mar 03; 292(9):3900-3908. PubMed ID: 28077575
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
    Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G.
    Nat Immunol; 2017 Aug 03; 18(8):889-898. PubMed ID: 28604720
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML.
    Mol Immunol; 2016 May 03; 73():69-75. PubMed ID: 27058641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.